News | Heart Failure | November 21, 2019

Investigational Drug Vericiguat Reduced the Risk of Heart Failure Hospitalization in VICTORIA Trial

Results show Merck and Bayer’s new drug reduced cardiovascular death in patients with worsening chronic heart failure with reduced ejection fraction
 

Heart failure VICTORIA TrIal a success. Dave Fornell

November 21, 2019 — Merck announced the results from the Phase 3 VICTORIA Study evaluating the efficacy and safety of vericiguat, met the primary efficacy endpoint for reducing the risk of heart failure hospitalization and cardiovascular death in patients with worsening chronic heart failure with reduced ejection fraction (HFrEF). The new drug outperformed patients given a placebo in combination with available heart failure therapies. 

Vericiguat is being jointly developed by Merck and Bayer AG. It is a soluble guanylate cyclase (sGC) stimulator being developed to treat patients with worsening chronic heart failure.

The drug company said the results of the VICTORIA study will be presented at an upcoming medical meeting in 2020.

“VICTORIA is the first large contemporary outcomes study to focus exclusively on a population with worsening chronic heart failure who have a high risk for cardiovascular mortality and repeated heart failure hospitalizations. We are pleased vericiguat met this primary endpoint and look forward to sharing the detailed findings of the study,” said Roy Baynes, M.D., Ph.D., senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

“Heart failure affects more than 60 million patients worldwide. Despite advances in therapies and prevention efforts, the cardiovascular event rates remain high,” said Joerg Moeller, M.D., member of the Executive Committee of Bayer AG's Pharmaceutical Division and head of Research and Development. “There is a high unmet need for new treatment options to reduce the risk of death and hospitalizations. We are pleased with the positive outcome with vericiguat as the first sGC stimulator evaluated in patients with worsening chronic heart failure with reduced ejection fraction.”

 

VICTORIA Trial Details

The VICTORIA study is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, Phase 3 study of vericiguat versus placebo when given in combination with available heart failure therapies in patients with worsening chronic heart failure with reduced ejection fraction (HFrEF) following a decompensation event, defined as heart failure hospitalization or receiving an intravenous diuretic for heart failure without hospitalization. 

The primary endpoint of the study is the composite of time to first occurrence of cardiovascular death or heart failure hospitalization. Secondary endpoints include time to occurrence of cardiovascular death, time to first occurrence of heart failure hospitalization, time to total heart failure hospitalizations (including first and recurrent events), time to the composite of all-cause mortality or heart failure hospitalization, and time to all-cause mortality. The study enrolled 5,050 patients who were randomized to receive either vericiguat once daily (titrated up to 10 mg) or placebo when given in combination with available heart failure therapies. 

The study, which was co-sponsored by Merck and Bayer, was conducted in collaboration with the Canadian VIGOUR Centre and the Duke Clinical Research Institute in more than 600 centers in 42 countries.

What is Heart Failure With Reduced Ejection Fraction

Heart failure with reduced ejection fraction (HFrEF), formerly known as systolic heart failure, is characterized by the compromised ability of the heart to eject blood sufficiently during its contraction phase. In the U.S., 6.5 million people have heart failure, and approximately 40-50% of these patients have HFrEF. Annually, approximately 30% of patients with symptomatic chronic heart failure will experience worsening of the disease, which is marked by progressive symptoms and/or a recent heart failure event. Approximately half of patients with worsening chronic HFrEF are rehospitalized within 30 days of the worsening event, and an estimated one in five patients with worsening chronic HFrEF will die within two years.

For more information: www.merck.com 

 

Find links to all the AHA late-breaking trials and other key news.

Related Content

Clinical trial quality data can be derived from national cardiovascular registries, which may change how trials are performed in the future.

Clinical trial quality data can be derived from national cardiovascular registries, which may change how trials are performed in the future. Getty Images

News | Cardiovascular Clinical Studies | June 24, 2021
June 24, 2021 — Data captured in American College of Cardiology (ACC)...
Heavily calcified coronary arteries seen on a CT scan of the heart. Research at the New York Institute of Technology will create blood flow modeling to show the impact of calcium in arteries as part of a project to develop treatments to remove calcium.

Heavily calcified coronary arteries seen on a CT scan of the heart. Research at the New York Institute of Technology will create blood flow modeling to show the impact of calcium in arteries as part of a project to develop treatments to remove calcium. 

News | Cardiovascular Clinical Studies | January 27, 2021
January 27, 2021 — A New York Institute of Technology research te
Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

News | Cardiovascular Clinical Studies | July 22, 2020
July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to re
The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...